Cross-cutting concerns:

• Countries
  • Data
  • Statistics
    • Death rates (by age group, comorbidities, vaccination status)
    • Excess Mortality
  • Policies
    • Mandates
    • Lockdowns
    • Passports
    • Timeline (History)
• Treatments
  • Outpatient
    • Protocols
  • Drugs
    • HCQ
    • IVM
    • Fluvoxamine
• Advocates
  • Doctors
  • Researchers
  • Influencers

We need a page that links to all the official country data. (Probably already exists)

• Understand the death rate by age and comorbidities and how it compares to influenza for as many countries as we can find.
• Compare the numbers by Alpha vs Beta variants

• Alternative views (Name, Credentials, Profession, Summary)
  • Mathew Crawford (Statistics)
  • Steve Kirsch (Advocate, Philanthropist)
  • Robert F. Kennedy Jr.
  • Peter McCullough
  • Jessica Rose
  • Jayanta Bhattacharya
  • Zedenko
  • Norman Fenton, Statistics
  • Filipe Rafaeli
  • Alex Berenson (Author, Investigative Journalist) Wrote “Pandemia”
  • Luc Montagnier
  • Didier Raoult
• Resources (Websites)
  • https://brownstone.org
  • FLCCC
  • ivmmeta
• Outpatient Protocols
  • Didier Raoult
  • Zedenko
  • FLCCC IMAP
  • Dr. Shankara Chetty

• Look into nasal, mouth and throat wash once infected.
• Psychology, mass psychosis and hysteria
• Nomenclature (Insisting on using the correct words. Don't allow the main stream narrative to define the “labels”. Propose better alternatives instead.)
  • Anti-Vax → Pro-Choice or “Healthy sceptic”
  • Conspiracy theorist → Pessimistic realist

• Software development
  • Complex project developed over months using a “waterfall” approach
  • No unit tests
  • No integration tests
  • No user acceptance tests
  • Odds of delivering a perfect working solution that meets all the user requirements and has no critical bugs?

• Developing a vaccine recipe for mass production is very different to developing a recipe for a small trial.
• The manufacturing hurdles and obstacles that need to be overcome are significant and typically take months to resolve. I am not familiar with new mRNA technologies to understand how they were able to resolve fundamental manufacturing issues so quickly. In other words we are talking about 2 miracles in a very short time frame. Developing the recipe for trials is one thing. Getting it ready for mass production is another.